Catalogo Articoli (Spogli Riviste)

OPAC HELP

Titolo:
Surrogate markers of response to cancer immunotherapy
Autore:
Morse, MA; Clay, TM; Hobeika, AC; Mosca, PJ; Lyerly, HK;
Indirizzi:
Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA Duke Univ Durham NC USA 27710 iv, Med Ctr, Dept Med, Durham, NC 27710 USA Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA Duke Univ Durham NC USA 27710 v, Med Ctr, Dept Surg, Durham, NC 27710 USA Duke Univ, Med Ctr, Dept Pathol & Immunol, Durham, NC 27710 USA Duke UnivDurham NC USA 27710 Dept Pathol & Immunol, Durham, NC 27710 USA
Titolo Testata:
EXPERT OPINION ON BIOLOGICAL THERAPY
fascicolo: 2, volume: 1, anno: 2001,
pagine: 153 - 158
SICI:
1471-2598(200103)1:2<153:SMORTC>2.0.ZU;2-P
Fonte:
ISI
Lingua:
ENG
Soggetto:
COLONY-STIMULATING FACTOR; CD8(+) T-CELLS; AUTOLOGOUS MELANOMA-CELLS; STAGE-IV MELANOMA; CLINICAL-PHASE-I; PERIPHERAL-BLOOD; DENDRITIC CELLS; ELISPOT-ASSAY; IMMUNE-RESPONSE; FLOW-CYTOMETRY;
Keywords:
cytotoxic T-lymphocytes; ELISPOT; intracellular cytokine; immunologic monitoring;
Tipo documento:
Editorial Material
Natura:
Periodico
Settore Disciplinare:
Clinical Medicine
Citazioni:
41
Recensione:
Indirizzi per estratti:
Indirizzo: Morse, MA Duke Univ, Med Ctr, Dept Med, Box 3233, Durham, NC 27710 USA Duke Univ Box 3233 Durham NC USA 27710 233, Durham, NC 27710 USA
Citazione:
M.A. Morse et al., "Surrogate markers of response to cancer immunotherapy", EXPERT OP B, 1(2), 2001, pp. 153-158

Abstract

Clinically effective cancer immunotherapy has been sought for more than 100 years and has been recently applied most successfully in strategies that passively deliver immune effectors such as monoclonal antibodies (anti-CD20for lymphoma and anti-FER2/neu for breast cancer), donor lymphocyte infusions in chronic myelongenous leukemia and non-myeloablative allogeneic peripheral blood progenitor transplants for renal cell carcinoma. There is mounting enthusiasm for strategies employing active stimulation of antitumour immune responses. These include vaccines based on tumour antigen proteins andpeptides, autologous, allogeneic or gene-modified tumour cells, dendritic cells and antigen-encoding, viral vector constructs. Indeed, randomised Phase In clinical trials of autologous tumour cell vaccines for colorectal cancer demonstrated an improvement in disease free survival and a trend towardimproved overall survival [1]. Despite these preliminary successes, it is clear that the many strategies under development cannot all be evaluated for survival benefit in large clinical trials that require many years, patients and resources to complete. This highlights the need to develop intermediate markers to help prioritise which agents to test in prospective randomised Phase III trials.

ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 23/01/20 alle ore 18:27:19